196 related articles for article (PubMed ID: 23187882)
1. Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity.
Shiraishi K; Mimura K; Izawa S; Inoue A; Shiba S; Maruyama T; Watanabe M; Kawaguchi Y; Inoue M; Fujii H; Kono K
Gastric Cancer; 2013 Oct; 16(4):571-80. PubMed ID: 23187882
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.
Okita R; Shimizu K; Nojima Y; Yukawa T; Maeda A; Saisho S; Nakata M
Oncol Rep; 2015 Dec; 34(6):2864-70. PubMed ID: 26503698
[TBL] [Abstract][Full Text] [Related]
4. Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Collins DM; Madden SF; Gaynor N; AlSultan D; Le Gal M; Eustace AJ; Gately KA; Hughes C; Davies AM; Mahgoub T; Ballot J; Toomey S; O'Connor DP; Gallagher WM; Holmes FA; Espina V; Liotta L; Hennessy BT; O'Byrne KJ; Hasmann M; Bossenmaier B; O'Donovan N; Crown J
Clin Cancer Res; 2021 Feb; 27(3):807-818. PubMed ID: 33122343
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
Barok M; Tanner M; Köninki K; Isola J
Breast Cancer Res; 2011 Apr; 13(2):R46. PubMed ID: 21510863
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.
Mimura K; Kono K; Maruyama T; Watanabe M; Izawa S; Shiba S; Mizukami Y; Kawaguchi Y; Inoue M; Kono T; Choudhury A; Kiessling R; Fujii H
Int J Cancer; 2011 Nov; 129(10):2408-16. PubMed ID: 21207425
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines.
Oshima Y; Tanaka H; Murakami H; Ito Y; Furuya T; Kondo E; Kodera Y; Nakanishi H
Gastric Cancer; 2014; 17(3):450-62. PubMed ID: 23948998
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.
Nam HJ; Ching KA; Kan J; Kim HP; Han SW; Im SA; Kim TY; Christensen JG; Oh DY; Bang YJ
Mol Cancer Ther; 2012 Feb; 11(2):439-51. PubMed ID: 22135232
[TBL] [Abstract][Full Text] [Related]
9. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Kalous O; Conklin D; Desai AJ; O'Brien NA; Ginther C; Anderson L; Cohen DJ; Britten CD; Taylor I; Christensen JG; Slamon DJ; Finn RS
Mol Cancer Ther; 2012 Sep; 11(9):1978-87. PubMed ID: 22761403
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
Collins DM; Gately K; Hughes C; Edwards C; Davies A; Madden SF; O'Byrne KJ; O'Donovan N; Crown J
Cell Immunol; 2017 Sep; 319():35-42. PubMed ID: 28735814
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab and lapatinib modulation of HER2 tyrosine/threonine phosphorylation and cell signaling.
Kostyal D; Welt RS; Danko J; Shay T; Lanning C; Horton K; Welt S
Med Oncol; 2012 Sep; 29(3):1486-94. PubMed ID: 21769502
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
[TBL] [Abstract][Full Text] [Related]
13. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
[TBL] [Abstract][Full Text] [Related]
14. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
Barok M; Tanner M; Köninki K; Isola J
Cancer Lett; 2011 Jul; 306(2):171-9. PubMed ID: 21458915
[TBL] [Abstract][Full Text] [Related]
16. TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line.
Deng X; Fogh L; Lademann U; Jensen V; Stenvang J; Yang H; Brünner N; Schrohl AS
Tumour Biol; 2013 Apr; 34(2):1161-70. PubMed ID: 23334956
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification.
Tanizaki J; Okamoto I; Takezawa K; Tsukioka S; Uchida J; Kiniwa M; Fukuoka M; Nakagawa K
Mol Cancer Ther; 2010 May; 9(5):1198-207. PubMed ID: 20424000
[TBL] [Abstract][Full Text] [Related]
18. Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.
Groeneweg JW; Hernandez SF; Byron VF; DiGloria CM; Lopez H; Scialabba V; Kim M; Zhang L; Borger DR; Tambouret R; Foster R; Rueda BR; Growdon WB
Clin Cancer Res; 2014 Dec; 20(24):6517-6528. PubMed ID: 25294905
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.
Scaltriti M; Verma C; Guzman M; Jimenez J; Parra JL; Pedersen K; Smith DJ; Landolfi S; Ramon y Cajal S; Arribas J; Baselga J
Oncogene; 2009 Feb; 28(6):803-14. PubMed ID: 19060928
[TBL] [Abstract][Full Text] [Related]
20. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]